Brief S2k guidelines - Cutaneous lymphomas;S2k Kurzleitlinie - Kutane Lymphome

JDDG - Journal of the German Society of Dermatology

Volumn 11, Issue SUPPL. 3, 2013, Pages 19-28

  Stadler, Rudolf ^a   Assaf, Chalid ^b   Klemke, Claus Detlev ^c   Nashan, Dorothee ^d   Weichenthal, Michael ^e   Dummer, Reinhard ^f   Sterry, Wolfram ^g  

^a KLINIKUM MINDEN   (Germany)

^b HELIOS KLINIKUM KREFELD   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Hospital of Dortmund   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTIBIOTIC AGENT; BENDAMUSTINE; BEXAROTENE; CHLORAMBUCIL; CLADRIBINE; DENILEUKIN DIFTITOX; DOXORUBICIN; FLUDARABINE; GEMCITABINE; METHOTREXATE; RITUXIMAB; ROMIDEPSIN; STEROID; VORINOSTAT;

ANTIBIOTIC THERAPY; ARTICLE; B CELL LYMPHOMA; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONSERVATIVE TREATMENT; CUTANEOUS T CELL LYMPHOMA; EPIDEMIOLOGY; HUMAN; IMMUNOHISTOLOGY; INCIDENCE; LOCAL THERAPY; LOW DRUG DOSE; LYMPHOMATOID PAPULOSIS; MAINTENANCE THERAPY; MYCOSIS FUNGOIDES; NK T CELL LYMPHOMA; PALPATION; PRACTICE GUIDELINE; PRIMARY TUMOR; PUVA; SEZARY SYNDROME; SKIN LYMPHOMA; SUBCUTANEOUS T CELL LYMPHOMA; THORAX RADIOGRAPHY; TOPICAL TREATMENT; WHOLE BODY CT;

DERMATOLOGY; GERMANY; HUMANS; LYMPHOMA; MEDICAL ONCOLOGY; PRACTICE GUIDELINES AS TOPIC; SKIN NEOPLASMS;

EID: 84876220414     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/ddg.12015_5     Document Type: Article

References (39)

1. Weinstock MA. Epidemiology of mycosis fungoides. Semin Dermatol 1994; 13: 154-9.
2. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 2007; 143: 854-9.
3. Assaf C, Gellrich S, Steinhoff M, Nashan D, Weisse F, Dippel E, et al. Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG). J Dtsch Dermatol Ges 2007; 5: 662-8.
4. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHOEORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-85.
5. Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, et al. European Organization for Research and Treatment of Cancer; International Society for Cutaneous Lymphoma. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous Bcell lymphomas. Blood 2008; 112: 1600-9.
6. Klemke CD, Dippel E, Dembinski A, Pönitz N, Assaf C, Hummel M, et al. Clonal T cell receptor gamma-chain gene rearrangement by PCR-based GeneScan analysis in the skin and blood of patients with parapsoriasis and early-stage mycosis fungoides. J Pathol 2002; 197: 348-54.
7. Tsai EY, Taur A, Espinosa L, Quon A, Johnson D, Dick S, et al. Staging accuracy in mycosis fungoides and Sézary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol 2006; 142: 577-84.
8. Kuo PH, McClennan BL, Carlson K, Wilson LD, Edelson RL, Heald PW, Girardi M. FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma. Mol Imaging Biol 2008; 10: 74-81.
9. Feeney J, Horwitz S, Gönen M, Schöder H. Characterization of T-cell lymphomas by FDG PET/CT. AJR Am J Roentgenol 2010; 195: 333-40.
10. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-22.
11. Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 479-84.
12. Assaf C, Hummel M, Steinhoff M, Geilen CC, Orawa H, Stein H, et al. Early TCR-beta and TCR-gamma PCR detection of T-cell clonality indicates minimal tumor disease in lymph nodes of cutaneous T-cell lymphoma: diagnostic and prognostic implications. Blood 2005; 105: 503-10.
13. Fraser-Andrews EA, Mitchell T, Ferreira S, Seed PT, Russell-Jones R, Calonje E, et al. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides. Br J Dermatol 2006; 155: 756-62.
14. Kamstrup MR, Lindahl LM, Gniadecki R, Iversen L, Skov L, Petersen PM, et al. Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an openlabel prospective phase II study. Br J Dermatol 2012; 166(2): 399-404.
15. Smith BD, Wilson LD. Cutaneous lymphomas. Semin Radiat Oncol 2007; 17: 158-68.
16. Stadler R. Optimal combination with PUVA: rationale and clinical trial update. Oncology (Williston Park) 2007; 21(2 Suppl 1): 29-32.
17. Stadler R, Otte HG, Luger T, Henz BM, Kühl P, Zwingers T, Sterry W. Prospective randomized multicenter clinical trial on the use of interferon - 2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92: 3578-81.
18. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C, Yocum RC; Bexarotene Worldwide Study Group. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456-71.
19. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC; Worldwide Bexarotene Study Group. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent earlystage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 581-93.
20. Assaf C, Bagot M, Dummer R, Duvic M, Gniadecki R, Knobler R, et al. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol 2006; 155: 261-6.
21. Gniadecki R, Assaf C, Bagot M, Dummer R, Duvic M, Knobler R, et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol 2007; 157: 433-40.
22. Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 1870-7.
23. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109-15.
24. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 4485-91.
25. Marchi E, Alinari L, Tani M, Stefoni V, Pimpinelli N, Berti E, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005; 104: 2437-41.
26. Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2006; 7: 51-8.
27. Wollina U, Dummer R, Brockmeyer NH, Konrad H, Busch JO, Kaatz M, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 2003; 98: 993-1001.
28. Booken N, Weiss C, Utikal J, Felcht M, Goerdt S, Klemke CD. Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sézary syndrome. J Dtsch Dermatol Ges 2010; 8: 428-38.
29. Bernengo MG, Quaglino P, Comessatti A, Ortoncelli M, Novelli M, Lisa F, Fierro MT. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. Haematologica 2007; 92: 784-94.
30. Yu JB, McNiff JM, Lund MW, Wilson LD. Treatment of primary cutaneous CD30+ anaplastic large-cell lymphoma with radiation therapy. Int J Radiat Oncol Biol Phys 2008; 70: 1542-5.
31. Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011; 118: 4024-35.
32. Assaf C, Gellrich S, Whittaker S, Robson A, Cerroni L, Massone C, et al. CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer. J Clin Pathol 2007; 60: 981-9.
33. Willemze R, Jansen P, Cerroni L, Berti E, Santucci M, Assaf C, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification and prognostic factors. An EORTC Cutaneous Lymphoma Group Study of 83 Cases. Blood 2008; 111: 838-45.
34. Dummer R, Assaf C, Bagot M, Gniadecki R, Hauschild A, Knobler R, et al. Maintenance therapy in cutaneous T-cell lymphoma: who, when, what? Eur J Cancer 2007; 43: 2321-9.
35. Mehnert A, Petersen C, Koch U. Empfehlungen zur Psychoonkologischen Versorgung im Akutkrankenhaus. Zeitschrift für Medizinische Psychologie 2003; 12: 77-84.
36. Loscalzo M, Clark KL, Holland J. Successful strategies for implementing biopsychosocial screening. Psycho- Oncology 2011; 20: 455-62.
37. Holland JC, Andersen B, Breitbart W. Distress Management. J Natl Compr Canc Netw 2010; 8: 448-85.
38. Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer 2006; 107(10): 2504-11.
39. Sampogna F, Frontani M, Baliva G, Lombardo GA, Alvetreti G, Di Pietro C, Tabolli S, Russo G, Abeni D. Quality of life and psychological distress in patients with cutaneous lymphoma. Br J Dermatol 2009; 160(4): 815-22.